05:13 AM EDT, 04/10/2024 (MT Newswires) -- ALX Oncology Holdings ( ALXO ) said Tuesday that data from the ongoing phase 1/2 trial of evorpacept, in combination with standard rituximab and lenalidomide, in patients with indolent and aggressive relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated the combination's "promising initial activity."

The company said the clinical trial enrolled 20 patients, with a best overall response rate of 94% and a complete response rate of 83%, though the "median duration of response was not reached." ALX said the combination was also well tolerated, without dose-limiting toxicities.

ALX said patient enrollment is open for the phase 2 portion of the study.

Price: 12.4, Change: +0.06, Percent Change: +0.49